Brief: Botanix Pharmaceuticals Says Sofdra Net Revenue Amounted To A$7.1 Million In Q1 FY26
20/10/2025 02:18
Oct 20 (Reuters) - Botanix Pharmaceuticals Ltd BOT.AX: BOTANIX QUARTERLY ACTIVITIES REPORT AND APPENDIX 4C Q1 FY26 SOFDRA NET REVENUE TO A$7.1 MILLION IN Q1 FY26 Further company coverage: BOT.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Botanix Pharmaceuticals
See all newsBrief: Botanix Pharmaceuticals Receives Notice Of Allowance For Additional US Patent Covering Sofdra Drug Substance
Brief: Botanix Pharmaceuticals Appoints Paul Seaback As Chief Operating Officer
Brief: Botanix Pharmaceuticals Reaches Term Sheet Agreement With Second API Supplier
Botanix Pharmaceuticals jumps on supply agreement with PPL Pharma Solutions
Brief: Botanix Pharmaceuticals Posts HY Loss Attributable A$33.2 Million